19:59 , Apr 11, 2017 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: SNPs SNPs on five genomic loci could help predict the risk of glioblastoma multiforme (GBM) and SNPs on eight genomic loci could help predict the risk of non-GBM glioma. Genome-wide association studies in 12,496 glioma...
07:00 , May 21, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: mRNA levels in tumor exosomes as markers of response to cancer treatment

Biomarkers TECHNOLOGY: Plasma Markers A microfluidics chip-based method for detecting mRNA in tumor exosomes could help monitor response to cancer therapies. The immuno-magnetic exosome RNA (iMER) platform measures exosomal levels of mRNA via on-chip enrichment of exosomes...
08:00 , Nov 20, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Ischemia/reperfusion injury N-methylpurine-DNA glycosylase (MPG; APNG; AAG) Mouse studies suggest inhibiting DNA base excision repair initiated...
08:00 , Jan 20, 2014 |  BC Week In Review  |  Company News

Celgene, NantWorks deal

Celgene partnered with the NantBioscience subsidiary of Patrick Soon-Shiong's NantWorks to develop a pipeline of cancer drugs using the nanoparticle albumin-bound (nab) technology Celgene gained in its acquisition of Soon-Shiong's former company, Abraxis Bioscience Inc....
08:00 , Jan 26, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer N-Methylpurine-DNA glycosylase (MPG; APNG) A study in cells and in...
07:00 , Jul 25, 2005 |  BC Week In Review  |  Company News

GenoSpectra, National Center for Scientific Research deal

Genospectra received an exclusive worldwide license to the center's MPG drug delivery technology. The parties also partnered to develop a panel of delivery reagents to transfer molecules into live cells. Genospectra has exclusive marketing rights...
07:00 , Jun 24, 2002 |  BioCentury  |  Politics, Policy & Law

NIH plans cause a stir abroad

In March, the NIH made a little-noticed announcement of plans that will affect the right of ownership to inventions made under funding agreements (grants, cooperative agreements, contracts, subgrants, and subcontracts) with foreign entities. In Europe...
07:00 , Jun 24, 2002 |  BioCentury  |  Politics, Policy & Law

Germany to increase biotech funding

The German research ministry BMBF last week announced it was planning to increase its biotech funding for 2003 by 6.5% from E660 million ($624 million) to E703 million ($665 million). Funding for research proposals in the...